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necessary to refine the diagnostic cri-
teria of both entities.
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Thymic Small Cell
Carcinoma Shows
Marked Response to
Amrubicin
To the Editor:
Thymic small cell carcinoma (small
cell carcinoma, neuroendocrine type ac-
cording to the World Health Organiza-
tion histologic classification) is a rare
aggressive mediastinal neoplasm, and
the optimal treatment remains unde-
fined. In this report, we describe a case
of thymic small cell carcinoma that
showed marked response to second-line
chemotherapy with single-agent amrubi-
cin (AMR), a synthetic anthracycline
analogue and potent deoxyribonucleic
acid topoisomerase II inhibitor.
A 57-year-old man was diagnosed
to have thymic small cell carcinoma
with pericardial sac invasion, pleural
dissemination and pulmonary metastasis
(stage IVb according to the classifica-
tion proposed by Masaoka et al). The
patient was initially treated by combina-
tion chemotherapy with paclitaxel and
carboplatin, in September 2006. Four
cycles of the chemotherapy were admin-
istered, and partial response was con-
firmed. However, regrowth of the mass
in the anterior mediastinum and that of
the pulmonary metastasis were observed
(Figure 1A). In addition, the serum lev-
els of neuron-specific enolase (80 ng/
ml) and progastrin-releasing peptide
(ProGRP, 515 ng/ml) were also elevated
(Figure 2). For the treatment in the sec-
ond-line setting, AMR administration
was begun in May 2007 at the dose of 40
mg/m2/d on days 1 to 3, every 3 weeks.
A chest computed tomography after four
cycles of AMR treatment demonstrated
a marked reduction in the size of the
anterior mediastinal mass and that of the
pulmonary metastasis, confirming par-
tial response (Figure 1B). Both the se-
rum neuron-specific enolase and Pro-
GRP levels decreased to their respective
normal ranges (Figure 2). The adverse
events related to AMR were no higher
than grade 1 in severity, according to
the Common Toxicity Criteria for Ad-
verse Events, Version 3.0 grading sys-
tem, proposed by the National Cancer
Institute. Only grade 1 neutropenia
and leukopenia were observed. After
seven cycles of AMR treatment, the
chest computed tomography obtained
in January 2008 revealed regrowth of
the anterior mediastinal mass and the
serum level of ProGRP was also ele-
vated. Although, subsequent treatments
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FIGURE 1. A, Computed tomography before administration of AMR. B, Marked
diminution in size of the mass in the anterior mediastinum.
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FIGURE 2. Clinical course and serum levels of neuron specific enolase (NSE) and
progastrin-releasing peptide (ProGRP).
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(third-line chemotherapy with gemcitab-
ine, fourth-line therapy with irinotecan,
and fifth-line therapy with a combina-
tion of carboplatin and paclitaxel) were
administered with disease progression,
no responses to these treatments were
observed, and the patient died in No-
vember 2008.
Several reports have indicated the
efficacy of combination regimens con-
taining cisplatin and doxorubicin, such
as Cisplatin  Doxorubicin  Vincris-
tine  Cyclophosphamide and Cisplatin
 Vincristine  Doxorubicin  Etopo-
side, against thymic carcinoma.1,2 Conse-
quently, doxorubicin has been considered
as highly reliable agent against thymic
carcinoma. AMR is a totally synthetic an-
thracycline, and has been demonstrated to
have equivalent or stronger antitumor ef-
fect as compared with doxorubicin in an
experimental animal model.3 Phase II
studies with single-agent AMR in previ-
ously treated extensive small cell lung
cancer have shown variable clinical re-
sponses and survivals.4,5 Thus, it might be
reasonable to suppose that AMR, an an-
thracycline, is not only a reliable agent
against thymic carcinoma, but also against
thymic small cell carcinoma. To our
knowledge, this is the first report to sug-
gest the activity of AMR against advanced
thymic small cell carcinoma in the sec-
ond-line setting. AMR can be an active
agent against advanced thymic small cell
carcinoma.
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